Cargando…

Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera

Highly transmissible SARS-CoV-2 variants identified in India and designated B.1.617, Kappa (B.1.617.1), Delta (B.1.617.2), B.1.618, and B.1.36.29 contain spike mutations L452R, T478K, E484K, E484Q, and N440K located within the spike receptor-binding domain and thus could contribute to increased tran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tada, Takuya, Zhou, Hao, Dcosta, Belinda M., Samanovic, Marie I., Mulligan, Mark J., Landau, Nathaniel R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541826/ https://www.ncbi.nlm.nih.gov/pubmed/34723159 http://dx.doi.org/10.1016/j.isci.2021.103341

Ejemplares similares

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
por: Tada, Takuya, et al.
Publicado: (2021)

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2022)

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
por: Tada, Takuya, et al.
Publicado: (2022)

Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model
por: Tada, Takuya, et al.
Publicado: (2023)

Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent
por: Zhang, Meng, et al.
Publicado: (2022)

Single-epitope T cell–based vaccine protects against SARS-CoV-2 infection in a preclinical animal model
por: Tada, Takuya, et al.
Publicado: (2023)

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies
por: Hu, Jie, et al.
Publicado: (2021)

Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants
por: Banerjee, Arinjay, et al.
Publicado: (2022)

Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes
por: Hein, Sascha, et al.
Publicado: (2021)

Sensitivity of SARS-CoV-2 antibody tests with late convalescent sera
por: Kannenberg, Judith, et al.
Publicado: (2021)

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
por: Dupont, Liane, et al.
Publicado: (2021)

High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens
por: Counoupas, Claudio, et al.
Publicado: (2022)

SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera
por: Kuzmina, Alona, et al.
Publicado: (2021)

Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody
por: Yue, Shuai, et al.
Publicado: (2021)

SARS corona virus peptides recognized by antibodies in the sera of convalescent cases
por: Guo, Jian-Ping, et al.
Publicado: (2004)

Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains
por: Pan, Ting, et al.
Publicado: (2021)

Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern
por: Yu, Xiaoqi, et al.
Publicado: (2022)

Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera
por: Hu, Jie, et al.
Publicado: (2021)

Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera
por: Ha, Binh, et al.
Publicado: (2021)

Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection
por: Mu, Song, et al.
Publicado: (2022)

Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant
por: Richardson, Simone I., et al.
Publicado: (2022)

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
por: Supasa, Piyada, et al.
Publicado: (2021)

Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera
por: Zhou, Wenhao, et al.
Publicado: (2022)

Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant
por: Villas-Boas, Lucy Santos, et al.
Publicado: (2022)

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
por: Kuzmina, Alona, et al.
Publicado: (2021)

Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents
por: Ma, Chengbao, et al.
Publicado: (2022)

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster
por: Lusvarghi, Sabrina, et al.
Publicado: (2021)

An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2
por: Tada, Takuya, et al.
Publicado: (2020)

SARS-CoV-2 Delta and delta derivatives impact on neutralization of Covishield recipient sera
por: Sahay, Rima R., et al.
Publicado: (2022)

Cross-Neutralization of SARS-CoV-2-Specific Antibodies in Convalescent and Immunized Human Sera against the Bat and Pangolin Coronaviruses
por: Srisutthisamphan, Kanjana, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
por: Yahalom-Ronen, Yfat, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
por: Wang, Bei, et al.
Publicado: (2021)

Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
por: Cheng, Lin, et al.
Publicado: (2021)

Vectored immunoprophylaxis and treatment of SARS-CoV-2 infection in a preclinical model
por: Tada, Takuya, et al.
Publicado: (2023)

Restriction of SARS-CoV-2 replication by receptor transporter protein 4 (RTP4)
por: Kaur, Ramanjit, et al.
Publicado: (2023)

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies
por: Lusvarghi, Sabrina, et al.
Publicado: (2022)

Impact of mAb-induced A475V substitution on viral fitness and antibody neutralization of SARS-CoV-2 omicron variants in the presence of monoclonal antibodies and human convalescent sera
por: Viriyakitkosol, Ratchanont, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e5qc0b0ei36lt1e82k3d2kl80o